National Strategy: Chinas precision medicine is making big strides forward

Xinnuo Medicine 2018-09-28

At present, the precision medical industry cluster represented by the United States and China and Europe is taking shape.

In 2015, the Ministry of Science and Technology held the “National Precision Medical Strategy Expert Meeting” and established the China Precision Medical Strategy Expert Group. A total of 19 experts formed the National Precision Medical Strategy Expert Committee, and plans to invest 60 billion yuan by 2030. Precision medicine has risen in China as a "national strategy."

In recent years, China's policy in the field of precision medicine has been very intensive and is accelerating the follow-up of industry supervision. At the same time, the National Guide for Precision Medicine also puts forward the key directions of “queue, big data, biomarkers, precision prevention, and precise treatment”.

The Chinese version of the Precision Medical Program will be based on big data and use genetic sequencing as a tool to develop more targeted treatments for specific diseases and specific patients. Therefore, big data is the foundation of precision medicine in human genome sequencing technology. Driven by biomedical analysis technology and big data analysis tools, the precision medical market is growing rapidly.

Focusing on the world, tumor-based, precision medical industry covering the entire process from early screening, assisted diagnosis, accompanying diagnosis to precise treatment has been formed.

Throughout the country, the intensive release of policies, the increasing incidence of cancer and mortality, and the continuous breakthrough in precision medical technology have jointly promoted the formation of the domestic precision medical industry in recent years, with the exception of Beishangguang. In addition, areas with better medical technology accumulation in the central and eastern regions represented by Shandong, Jiangsu and Zhejiang are becoming the bridgeheads for the development of precision medicine.

Among them, technologies such as PCR and antibody drugs have developed earlier and are more mature, and the gene sequencing enterprises have also grown rapidly with the development of technology in recent years. Only 1395 companies in the three sub-areas of gene sequencing, PCR and antibody drugs occupy the country. Most of the time.

Since 2013, a total of 243 publicly disclosed financings have occurred in China's precision medical field. Except for the 58 undisclosed amounts, the single transaction amount of 67 transactions exceeded 100 million yuan. According to the statistics of 148 transactions that explicitly disclosed the specific amount, the total amount of financing has grown very rapidly, from 2.2 billion in 2013 to nearly 10 billion in 2016.

On the whole, early financing still accounts for the majority, the average amount is low, while the amount of financing in the middle and late period is greatly reduced, but the large amount of financing is written. The average amount of the round B and later has exceeded 100 million, D round and The average amount of the eight previous financing bills exceeded 300 million.

From a time perspective, 2015 is the year of the outbreak of precision medical capital market. The significant decline in quantity and total amount in 2017 reflects that the early capital layout has been basically completed.

From the field of subdivision technology, gene sequencing, liquid biopsy, antibody drugs, etc. are the key areas of capital distribution. In these three areas, a total of 195 financings were completed, involving a total amount of 20.84 billion yuan. Among them, the highest amount of financing is antibody drugs, 62 financing reached 11.39 billion yuan, compared with 101 financing in the field of gene sequencing, a total of 6.11 billion yuan.

In China, the gene sequencing industry presents a situation in which upstream is monopolized by foreign companies, and Chinese companies are concentrated in the middle and lower reaches. As a participating country of the Human Genome Project (HGP), China's gene sequencing industry has grown rapidly and its financing is active. In the 101 financings, there are more than 28 billion singles, and it is expected to reach a market scale of 10 billion yuan by 2020. At the same time, the middle and lower reaches of the industrial chain are developing very rapidly, and the industry leader extends to the upstream kit components.

The field of reproduction is the most mature application area for gene sequencing. More than 50% of the sales of leading companies come from NIPT. The most mature Huada gene and Berry and Kang jointly occupy more than 90% of the existing market of NIPT. . However, the current market penetration rate of NIPT is still around 10%, and there is still a large amount of market space.

In recent years, the rapid development of liquid biopsy domestic financing a total of 32, there are 11 singles over 100 million, an average of 330 million yuan each, will be expected to replace tissue biopsy as the main means of early screening of cancer.

With the development of high-throughput sequencing and digital PCR technology, ctDNA has gradually entered the market. In the short term, liquid biopsy will be driven by technology, and companies that master high-efficiency CTC and ctDNA technologies will have an advantage in market competition.

China has a good research and development basis in the field of antibody drugs. As of May 2017, the statistics show that China has become the second largest in the world in the field of antibody drug research and development, with a large number of excellent enterprises, a total of 384 antibody drugs in Research and market, while monoclonal antibody as the focus of current research on antibody drugs, will usher in the industry's outbreak in the next 5 to 10 years.

Precision medicine is a multidisciplinary and systematic project. The development of the industry requires the coordinated development of multiple industries, governments and capital. The global precision medical market has already exceeded 60 billion US dollars, and will maintain a growth rate of around 15% in the next 3 to 5 years, while China is expected to achieve growth rate of more than 20%.

In the future, with the further breakthrough of medical treatment technology and the improvement of medical insurance payment level, precision medical treatment will be applied to the health management and decision-making of individual life cycle. Invisible champions in industry leaders and sub-sectors are constantly emerging, and technological breakthroughs and the application of combined scenarios will be opportunities for new entrants.

For example, the ability of artificial intelligence to process big data will help the rapid development of precision medicine. Enterprises that optimize data processing and improve the degree of dataization through AI, big data and cloud computing will occupy a place in the field of precision medicine.


Hot News

Contact Us

Jinan Xinnuo Pharmaceutical Technology Co., Ltd.

Service hotline: +86- 18615688656 18653156686

E_mail:sales@xinnuopharma.com sabrina@xinnuopharma.com

Send Email

Copyright: Jinan Xinnuo Pharmaceutical Technology Co., Ltd. All rights reserved.   Powered by:MRWL